Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia

Naveen Pemmaraju, Aaron T. Gerds, Jingbo Yu, Shreekant Parasuraman, Anne Shah, Ann Xi, Shambhavi Kumar, Robyn M. Scherber, Srdan Verstovsek

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Patients with polycythemia vera (PV) and essential thrombocythemia (ET) have increased thrombotic risk. This retrospective, real-world analysis of Medicare patients (age ≥ 65 years) newly diagnosed with high-risk PV or intermediate-/high-risk ET compared mortality risk among those with versus without thrombotic events during the study period. Patients diagnosed with PV or ET with ≥ 1 inpatient or ≥ 2 outpatient claims (January 1, 2010–December 31, 2017; index was date of first qualifying claim) were included. The study included 50,405 Medicare beneficiaries with PV and 124,569 with ET. During follow-up (median [range]: PV, 34.5 [0–97.3] months; ET, 25.5 [0–97.4] months), 14,334 patients (28.4%) with PV and 30,478 (24.5%) with ET experienced thrombotic events (most commonly ischemic stroke [PV, 46.0%; ET, 42.5%]. Mortality risk was increased for patients with versus without post-index thrombosis for both PV (adjusted hazard ratio [aHR; 95% CI], 18.6 [16.1–21.6]; P < 0.001) and ET (aHR [95% CI], 25.2 [23.1–27.5]; P < 0.001). Median survival was shorter for patients who experienced a thrombotic event ≤ 1 year post-index versus those who did not (PV, 5.1 years vs not reached; ET, 3.7 vs 6.7 years; both P < 0.001). These findings highlight the importance of thrombosis risk mitigation in PV and ET management.

Original languageEnglish (US)
Article number106809
JournalLeukemia Research
StatePublished - Apr 2022
Externally publishedYes


  • Essential thrombocythemia
  • Myeloproliferative neoplasms
  • Polycythemia vera
  • Survival
  • Thrombotic events

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia'. Together they form a unique fingerprint.

Cite this